Clairyon Unveils New Direction to Enhance Healthcare Quality and Patient Outcomes

Clairyon, the innovative rebranding of Healcisio, is marking a transformative era focused on growth, technology, and patient care. The exciting transition introduces Brenda Schmidt as the new CEO and incorporates Dr. Michael McCurdy as the Chief Medical Officer, both tasked with driving the company's mission forward. Aaron Boussina, the founder, will shift his focus to the role of Chief Technology Officer, prioritizing advancements in technology and product innovation.

The revitalization of Clairyon emphasizes its commitment to enhancing health systems with cutting-edge artificial intelligence solutions. These solutions provide key insights through continuous, multimodal monitoring of acute care patients. Automated data abstraction, real-time quality reporting, and predictive analytics represent just a fraction of Clairyon's capabilities, all aimed at improving patient outcomes and alleviating the burdens associated with chart abstraction.

Clairyon’s pursuit of excellence in healthcare AI has not gone unnoticed. The company has received over $1 million in Small Business Technology Transfer Research (STTR) funding, which has been instrumental in advancing solutions that empower clinicians, quality, and safety teams. These advancements have showcased substantial improvements in patient care, as seen in a recent publication in NEJM AI that highlighted a breakthrough in critical care quality automation with an astounding accuracy rate of over 90% in AI-generated SEP-1 reports.

Among Clairyon's most remarkable achievements is the reduction of sepsis mortality by 17% through rigorous, peer-reviewed studies. The company has made significant strides in the healthcare field, showcasing an enhancement of nearly 10% in SEP-1 bundle compliance. With technology already implemented in 62 hospital care units, Clairyon has positively impacted more than 150,000 lives. The company aims to expand its reach in the coming year through strategic partnerships with health systems and the deployment of new generative AI tools, focusing on enhancing outcomes for critically ill patients across diverse healthcare settings.

Shamim Nemati, a co-founder and Board Director, expressed confidence in the new leadership direction and clarified, "Our research has resulted in over 20 peer-reviewed articles demonstrating Clairyon’s ability to merge world-class research with practical solutions. These brand and leadership changes reflect our evolution as a company and our commitment to empowering clinicians with cutting-edge tools.” The transition in leadership is viewed as a crucial step towards expanding Clairyon's influence in the healthcare domain, enhancing the quality and affordability of care across health systems.

Clairyon invites health systems, researchers, and partners to rally together in its mission towards improving patient care quality. The company continues to execute its vision of transforming healthcare delivery through real-time monitoring solutions that identify safety events, quality gaps, and opportunities for improvement in patient care. This commitment to enhancing system-wide performance simplifies reporting, maximizes reimbursement, and ultimately elevates patient outcomes.

For further information about Clairyon’s innovative solutions and its commitment to healthcare improvement, visit www.clairyon.com.